Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma

PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic target of rapamycin (mTOR) inhibitor everolimus and ALK inhibitor crizotinib have...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Res Treat
Hoofdauteurs: Xu, Wendan, Kim, Ji-Won, Jung, Woo June, Koh, Youngil, Yoon, Sung-Soo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Korean Cancer Association 2018
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5912135/
https://ncbi.nlm.nih.gov/pubmed/28675026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2016.357
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items